Sunday September 7, 2014

16:15  Opening Ceremony

16:35  Portugal: the Right Place to build Partnerships in Health
Dr Joaquim CUNHA
(HEALTH CLUSTER PORTUGAL, Maia, Portugal)

16:50  Partnership between Public and Private Sources: Pharma and IMI Perspective
Dr Paul Peter TAK
(EFPIA, Brentford, United Kingdom)

17:10  EFMC Award Ceremony

17:35  The Nauta Award for Pharmacochemistry
Pursuing Compound Quality
Dr Paul LEESON
(GLAXOSMITHKLINE, Nuneaton, United Kingdom)

18:20  High Resolution Mass Spectrometry in Clinical Proteomics
Prof. Dr Matthias MANN
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Martinsried, Germany)

19:10  Welcome Reception
Monday September 8, 2014

08:30  The UCB-Ehrlich Award for Excellence in Medicinal Chemistry
Small Molecule Control Of Intracellular Protein Levels
Prof. Craig CREWS
(YALE UNIVERSITY, New Haven, CT, United States)

09:15  The Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery
Thermodynamics Assisted Drug Discovery
Dr György G. FERENCZY (HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
Prof. György KESERU (HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

10:00  Exhibition & Coffee

Session 1.1 Inflammation: the Common Link in Multifactorial Disorders?
10:30  Session Chair
Prof. Angeliki KOUROUNAKIS
(UNIVERSITY OF ATHENS, Athens, Greece)

10:35  Inflammation, Obesity and Metabolic Disease
Dr Ajay CHAWLA
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

11:15  CB2 Agonists Protect from Inflammation Related Kidney Damage and Fibrosis
Dr Uwe GREther
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

11:35  The Discovery of APD334, a Selective S1P1 Functional Antagonist
Dr Robert JONES
(ARENA PHARM, SAN DIEGO, United States)

11:55  Discovery of Small Molecule Ror? Modulators for the Treatment of Autoimmune Diseases
Dr Frank NARJES
(ASTRAZENECA, Gothenburg, Sweden)

Session 1.2 Computational Approaches To Guide Medicinal Chemistry
10:30  Session Chair
Prof. Helmut GRUBMÜLLER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

10:35  Mechanoenzymatics of Biomolecular Machines: Free Energies, Dynamics, Function
Prof. Helmut GRUBMÜLLER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

11:15  Efficient Determination Of Protein-Ligand Standard Binding Free Energies And Permeabilities With A Computational Microcalorimeter
Dr Chris CHIPOT
(UNIVERSITY OF ILLINOIS, Urbana, United States)

11:35  Binding Affinity Prediction from Molecular Simulation – Soon a Standard Method in Structure-Based Drug Design?
Dr Clara CHRIST
(BAYER, Berlin, Germany)

11:55  P-Glycoprotein/Membrane Role on Multidrug Resistance: Insights from In Silico Studies
Mr Ricardo FERREIRA
(FACULTY OF PHARMACY, UNIVERSITY OF LISBON, Lisbon, Portugal)

Session 1.3 Organic Synthesis that Changed Medicinal Chemistry
10:30  Session Chair
Dr Morten JORGENSEN
(H. LUNDBECK A/S, Valby, Denmark)

10:35  Recent Advances In Asymmetric Catalysis
Prof. Erick M. CARREIRA  
(ETH ZÜRICH, Zürich, Switzerland)

11:15  **New Stereoselective Organocatalytic Reactions for the Synthesis of Isoquinoline Alkaloids**

Prof. Pier Giorgio COZZI  
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

11:35  **Metalation of Polyfunctional Heterocyclic Compounds: Applications in Agrochemistry**

Dr Marc MOSRIN  
(BAYER CROPSCIENCE AG, Frankfurt am Main, Germany)

11:55  **Development of Novel Building Blocks to Accelerate Drug Discovery**

Dr Pavel MYKHAILIUK  
(ENAMINE, Kyiv, Ukraine)

12:15  **Exhibition & Lunch**

**Session 2.4 Combating Antibiotic Resistance**

13:15  **Session Chair**

Prof. Ada YONATH  
(WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel)


Prof. Erik BOETTGER  
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)

14:00  **Visualising Novel Macrolide Antibiotics Bound to Their Ribosomal Target**

Prof. Stephen SOUTHWAITE  
(UNIVERSITY OF SOUTHERN DENMARK, Odense, Denmark)

14:20  **The Ribosome as a Drug Target: Insights from Structural Investigations - Towards Rational Drug Design**

Dr Moran SHALEV-BENAMI  
(WEIZMANN INSTITUTE, Rehovot, Israel)

14:40  **Antagonists of the Pseudomonas Quinolone Signal Receptor (PQSR) as Promising Anti-Virulence Agents**

Dr Martin EMPTING  
(HELMHOLTZ-INSTITUTE FOR PHARMACEUTICAL RESEARCH SAARLAND, Saarbrücken, Germany)

**Session 2.5 Taming Natural Products: Novel Natural Products, Complex Synthesis, Mutasynthesis**

13:15  **Session Chair**

Prof. Anake KIJJOA  
(UNIVERSITY OF PORTO, Porto, Portugal)

13:20  **Natural Products as Driving Force for Innovation in Pharmaceutical Research and Development**

Dr Esther SCHMITT  
(NOVAARTIS, Basel, Switzerland)

14:00  **Sponging Off Nature for New Drug Leads**

Prof. Raymond ANDERSEN  
(UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada)

14:20  **Bioactive Secondary Metabolites From The Soil And Marine-Derived Fungi Of The Genus Neosartorya**

Prof. Anake KIJJOA  
(UNIVERSITY OF PORTO, Porto, Portugal)

14:40  **From Malaysian Biodiversity to the Total Synthesis of Dual Inhibitors of BCL-XL and MCL-1 Anti-Apoptotic Protein**

Dr Fanny ROUSSI  
(ICSN - CNRS, Gif sur Yvette, France)

**Session 2.6 Mechanism-Based Prediction of Drug-Induced Liver Injury**

(Eufeps Session)

13:15  **Session Chair**

Prof. Nico VERMEULEN  
(VU UNIVERSITY, Amsterdam, The Netherlands)

13:20  **Mechanism-Based Prediction of Drug-Induced Liver Injury**
Dr Christopher GOLDRING  
(UNIVERSITY OF LIVERPOOL, Liverpool, United Kingdom)  
14:00  Strategies to Identify and Manage the Risks of Chemically Reactive Drug Metabolites  
Prof. Nico VERMEULEN  
(VU UNIVERSITY, Amsterdam, The Netherlands)  
14:20  Being More Certain About Uncertainty In Computational Toxicology Modeling  
Dr Scott BOYER  
(KAROLINSKA INSTITUTET, Barcelona, Spain)  
14:40  Covalent Modification of Histones by Nevirapine - A Plausible Pathway to Nevirapine-Induced Cancers?  
Dr Alexandra ANTUNES  
(INSTITUTO SUPERIOR TÉCNICO, Lisbon, Portugal)  
15:00  Exhibition & Coffee  
15:30  MedChemComm Prize Winner : Phage Selection Of Bicyclic Peptides For Therapeutic Application  
Prof. Christian HEINIS  
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)  

Session 3.7 EFMC Session  
15:55  Session Chair  
Dr Phil JONES  
(UNIVERSITY OF DUNDEE, Glasgow, United Kingdom)  
16:00  The Open Phacts Discovery Platform - Semantic Data Integration For Medicinal Chemists  
Prof. Gerhard ECKER  
(UNIVERSITY OF VIENNA, Vienna, Austria)  
16:30  European Lead Factory - Game Changing For Innovative Medicines  
Dr Dimitrios TZALIS  
(TAROS CHEMICALS, Dortmund, Germany)  
17:00  Funding Opportunities with the Innovative Medicines Initiative 2  
Dr Colm CARROLL  
(INNOVATIVE MEDICINES INITIATIVE, Brussels, Belgium)  

17:30  Poster Session I and Networking  
19:30  End of the day  
20:30  Concert (free of charge, but subject to registration)
Tuesday September 9, 2014

08:30  Prize Ceremony

08:35  EFMC Prize for a Young Medicinal Chemist in Industry
       Design, Synthesis and Properties of Potent Inhibitors of Pseudomonas Aeruginosa Deacetylase LpxC
       Dr Grazia PIIZZI
       (NOVARTIS PHARMA, Basel, Switzerland)

08:55  EFMC Prize for a Young Medicinal Chemist in Academia
       Inhibitors and Substrates of the Human Lysine Deacylase Enzymes
       Prof. Christian A. OLSEN
       (UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

09:15  Plenary Lecture
       Dr Sabine HADIDA
       (VERTEX PHARMACEUTICALS, San Diego, United States)

10:00  Exhibition & Coffee

Session 4.8 Applications of Positron Emission Tomography in Drug Discovery (ACS Session I)

10:30  Session Chair
       Dr Sam BONACORSI
       (BRISTOL-MYERS SQUIBB, Princeton, United States)

10:35  PET Imaging: Synthesis of Radiopharmaceuticals and their Application in Personalized Medicine and Drug Discovery
       Dr Peter J.H. SCOTT
       (UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

11:15  A Rational Approach to the Development of Radioligands and PET Ligands for Drug Development
       Dr Chad ELMORE
       (ASTRAZENECA PHARMACEUTICALS, Mölndal, Sweden)

11:35  Design, Synthesis and Development of Lysophosphatidic Acid Receptor 1 (LPA1) PET Radioligands for Lung Receptor Occupancy Imaging
       Dr Sam BONACORSI
       (BRISTOL-MYERS SQUIBB, Princeton, United States)

       Dr Stefanie KRAMER
       (ETH ZÜRICH, Zürich, Switzerland)

Session 4.9 Decoding Disease: Liganding and Drugging Bromodomain Epigenetic Readers

10:30  Session Chair
       Prof. Stuart CONWAY
       (UNIVERSITY OF OXFORD, Oxford, United Kingdom)

10:35  BETting on Bromodomains: Developing Inhibitors of the Bromodomain-Acetyl-Lysine Interaction
       Prof. Stuart CONWAY
       (UNIVERSITY OF OXFORD, Oxford, United Kingdom)

11:15  A First In Class Chemical Probe For Family VIII Bromodomains
       Dr Dafydd OWEN
       (PFIZER, Cambridge, United States)

11:35  Epigenetic Drug Discovery: Small Molecule Inhibitors of Class IV Bromodomain Proteins
       Prof. Paul FISH
       (UCL SCHOOL OF PHARMACY, London, United Kingdom)
11:55 Interrogation the Bromodomain Family through Chemical Biology
Dr Steve BELLON
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

Session 4.10 Organic Synthesis: New Developments
(EuCHemS Session)
10:30 Session Chair
Prof. Péter MÁTYUS (SEMMELEVIS UNIVERSITY, Budapest, Hungary)
(THERMO FISHER SCIENTIFIC)
10:35 Experiences with Natural Product Total Synthesis
Prof. Alois FÜRSTNER
(MAX PLANCK INSTITUT FUR KOHLENFORSCHUNG, Muelheim an der Ruhr, Germany)
11:15 New Synthetic Routes of Nitrogen and Oxygen Heterocycles and Related Compounds
Prof. Artur M.S. SILVA
(UNIVERSITY OF AVEIRO, Aveiro, Portugal)
11:35 Fast and Safe Synthesis of Pharmaceutically Relevant Molecules
Prof. Thomas WIRTH
(UNIVERSITY OF CARDIFF, Cardiff, United Kingdom)
11:55 Metal Assisted Synthetic Approaches to Heterocyclic Small Molecules for the Treatment of Cardiovascular Diseases
Prof. Marko D. MIHOVILOVIC
(VIENNA UNIVERSITY OF TECHNOLOGY, Vienna, Austria)
12:15 Exhibition & Lunch

Session 5.11 Oncology: Kinases and Beyond
13:15 Session Chair
Dr Mario VARASI
(EUROPEAN INSTITUTE OF ONCOLOGY, Milano, Italy)
13:20 Therapeutic Opportunities Offered by the Excessive Lactate Production in Cancer
Prof. Filippo MINUTOLO
(UNIVERSITY OF PISA, Pisa, Italy)
14:00 Novel Anti-Cancer Treatment Targeting Vps34
Dr Jessica MARTINSSON
(SPRINT BIOSCIENCE, Stockholm, Sweden)
14:20 Exploiting Tumor Metabolic Vulnerabilities with Novel OxPhos Inhibitors
Dr Maria Emilia DI FRANCESCO
(UTMD ANDERSON CANCER CENTER, Houston, United States)
14:40 Discovery and Characterization of A-366, a Novel, Potent and Highly Selective Inhibitor of Histone Methyltransferase G9a
Dr Michael MICHAELIDES
(ABBVIE, North Chicago, United States)

Session 5.12 Recent Advances in Anti-infective Agents
(AFMC Session)
13:15 Session Chair
Dr Ming-Hua HSU
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)
13:20 Development of New Anti-Infective Agents and a Novel Delivery Strategy
Prof. Reuben JIH-RU HWU
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)
14:00 Synthesis of Anti-infective Cyclic Natural Products and Natural Product-like Compounds
Prof. Han-Young KANG
(CHUNGBUK NATIONAL UNIVERSITY, Cheongju, Korea, South)
14:20 Novel Boron-containing Anti-infective Agents
13:15  Session Chair

13:20  Integration of New Chemical Diversity and Design Approaches in Lead Generation
Dr Timothy GRESE
(ELI LILLY AND COMPANY, Indianapolis, United States)

14:00  The Impact of Polypharmacology on Lead Generation
Prof. Jordi MESTRES
(IMIM AND UNIVERSITY POMPEU FABRA, Girona, Spain)

14:20  Starting Small, Thinking Big: The Application of Fragment Based Drug Discovery to Lead Generation
Dr Steve WOODHEAD
(TAKEDA CALIFORNIA, San Diego, United States)

14:40  Discovery of the First and Only Small Molecule IL-17 Blockers
Dr Nils HANSEN
(VIPERGEN, Copenhagen, Denmark)

15:00  Exhibition & Coffee

15:30  Medicinal Chemistry Experts in Pharma are Helping us to Generate Freely Available Novel Probes in Order to Facilitate Target Discovery
Prof. Chas BOUNTRA
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

16:30  Poster Session II and Networking

18:30  End of the day
Wednesday September 10, 2014

08:30 IUPAC Richter Prize Lecture
Medicinal Chemistry, Quo Vadis? - The Changing Climate In R&D
Dr Helmut BUSCHMANN
(PHARMA CONSULTING AACHEN, Aachen, Germany)

09:15 Innovation Through Chemistry at the Interfaces of the Scientific Disciplines
Dr Martin MISSBACH
(NOVARTIS, Basel, Switzerland)

10:00 Exhibition & Coffee

Session 6.14 New Chemical Entities: Beyond Small Molecules

10:30 Session Chair
Prof. Stan VAN BOECKEL
(LEIDEN INSTITUTE OF CHEMISTRY, Leiden, The Netherlands)

10:35 Cyclic Peptides from the nature to the synthetic ones
Prof. Fernando ALBERICIO
(INSTITUTE FOR RESEARCH IN BIOMEDICINE, Durban , South Africa)

11:15 Successful Drug Discovery And Development Case Studies Of Protein Epitope Mimetics
Dr Daniel OBRECHT
(POLYPHOR, Allschwil, Switzerland)

11:35 Cell-Permeable Peptide Therapeutics to Effectively Access Intracellular Targets in Cancer Stem Cells
Dr Jörg VOLLMER
(NEXIGEN, Cologne, Germany)

11:55 Novel Inhibitors of Alzheimer’s Associated Beta-Secretase-Clusters of Heparan Sulfate
Dr Olga ZUBKOVA
(VICTORIA UNIVERSITY OF WELLINGTON, Lower Hutt , New Zealand)

Session 6.15 Novel Agents for the Treatment of C. Difficile
(ACS Session II)

10:30 Session Chair
Prof. Steven FIRESTINE
(WAYNE STATE UNIVERSITY, Detroit, United States)

10:35 Discovery and Development of Surotomycin for the Treatment of C. difficile
Dr Jared SILVERMAN
(CUBIST PHARMACEUTICALS, Lexington, United States)

11:15 Invited Lecture
Dr Terry BOWLIN
(MICROBIOTIX, Worcester, United States)

11:35 Targeting Spore Germination to Prevent Clostridium Difficile Infections
Dr Ernesto ABEL-SANTOS
(UNIVERSITY OF NEVADA, LAS VEGAS, Nevada, Las Vegas, United States)

11:55 Cadazolid: A New Antibiotic in Development for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Dr Philippe PANCHAUD
(ACTELION PHARMACEUTICALS LTD, Allschwil, Switzerland)

Session 6.16 Kinetic and Thermodynamic Aspects of Ligand Binding

10:30 Session Chair
Prof. György KESERU
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

10:35 Exploring the Dynamics of Ligand-Protein Interactions using SPR Biosensors
Prof. Helena DANIELSON  
(UPPSALA UNIVERSITY, Uppsala, Sweden)

11:15 **Breaking The Equilibrium Dissociation Constant Into Fragments: The Use Of Binding Kinetics And Thermodynamics In The Development Of Selective Ligands.**  
Prof. Iwan DE ESCH  
(VRIJE UNIVERSITEIT AMSTERDAM, Amsterdam, The Netherlands)

11:35 **Medicinal Chemistry Optimisation Of Binding Kinetics**  
Prof. Mike WARING  
(ASTRAZENECA, Newcastle upon Tyne, United Kingdom)

11:55 **CRTH2: Can Residence Time Help?**  
Dr Elena GOMEZ  
(ALMIRALL, BARCELONA, Spain)

12:15 Exhibition & Lunch

**Session 7.17 Recent Highlights in Medicinal Chemistry**

13:15 **Session Chair**  
Prof. Carlos MONTANARI  
(UNIVERSITY OF SAO PAULO, Sao Paulo, Brazil)

13:20 **Cebranopadol, a Novel, Potent Analgesic**  
Dr Henning STEINHAGEN  
(GRÜENTHAL, Verona, Italy)

13:40 **Discovery of BAY 1002670 - A Highly Potent and Selective Progesterone Receptor Modulator for Gynecological Therapies**  
Dr Wolfgang SCHWEDE  
(BAYER, Berlin, Germany)

14:00 **Design, Synthesis and Biological Evaluation of Potent and Selective Class IIA Histone Deacetylase Inhibitors as a Potential Therapy for Huntington's Disease**  
Dr Christopher LUCKHURST  
(BIOFOCUS, Saffron Walden, United Kingdom)

14:20 **Structure-Guided Design of Potent, Selective, Orally Bioavailable Tankyrase Inhibitors**  
Dr Erin DIMAURO  
(AMGEN, Cambridge, United States)

14:40 **Novel Potent Inhibitors of the Histone Demethylase KDM1A**  
Dr Paola VIANELLO  
(EUROPEAN INSTITUTE OF ONCOLOGY, Milan, Italy)

**Session 7.18 Hot Topics in Ion Channels**

13:15 **Session Chair**  
Prof. Brian COX  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Brighton, United Kingdom)

13:20 **An Introduction To Ion Channels As Drug Targets**  
Prof. Morten GRUNNET  
(LUNDBECK, Valby, Germany)

14:00 **CNV1014802, a Novel Nav1.7 Selective State-Dependent Sodium Channel Blocker for the Treatment of Chronic Pain: From Discovery to Phase 2 Clinical Study**  
Dr Gerard GIBLIN  
(CONVERGENCE PHARMACEUTICALS, Cambridge, United Kingdom)

14:20 **Pain-relieving Peptides Targeting Acid-Sensing Ion Channels**  
Dr Eric LINGUEGLIA  
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)

14:40 **Discovery of Ivacaftor (Vx-770), a Cfr Potentiator for the Treatment of Cystic Fibrosis in G551d Patients**  
Dr Sabine HADIDA  
(VERTEX PHARMACEUTICALS, San Diego, United States)

**Session 7.19 Allosteric Modulators for CNS Diseases**
13:15   Session Chair
       Dr Wolfgang FROESTL
       (AC IMMUNE, Lausanne, Switzerland)

13:20   Functional and Structural Insights into GPCR Allostery
       Prof. Arthur CHRISTOPOULOS
       (MONASH UNIVERSITY, Parkville, Australia)

14:00   Discovery of the mGlu5 Negative Allosteric Modulator RO4917523
       Dr Georg JAESCHKE
       (F. HOFFMANN-LA ROCHE, Basel, Switzerland)

14:20   Allosteric Protein Kinases Inhibitors for Neurodegenerative Diseases Therapies
       Prof. Ana MARTINEZ
       (INSTITUTO DE QUIMICA MEDICA-CSIC, Madrid, Spain)

14:40   Antibodies as Tools to Enable Small Molecule Drug Discovery
       Dr Marta WESTWOOD
       (UCB, Slough, United Kingdom)

15:00   Excursions

20:00   Banquet
Thursday September 11, 2014

Session 8.20 GPCR Structural Biology: New Therapeutic Opportunities?

08:30  Session Chair
Prof. Jan STEYAERT  
(VUB, Brussels, Belgium)

08:35  High End Design for GPCRs: Combining Protein Structure, Biophysical Data and Computational Water Network Energies
Dr. Jonathan MASON  
(HEPTARES THERAPEUTICS, Cambridge, United Kingdom)

09:15  Nanobody-Enabled Fragment Screening On Active-State Constrained GPCRs
Prof. Jan STEYAERT  
(VUB, Brussels, Belgium)

09:35  Covalent Agonists Facilitating Crystallisation of GPCRs
Prof. Peter GMEINER  
(FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)

09:55  Crystallographic Structures Enable the Discovery of Selective 5-HT1b Receptor Ligands through Virtual Screening
Dr David RODRIGUEZ DIAZ  
(STOCKHOLM UNIVERSITY, Solna, Sweden)

Session 8.21 Neglected Tropical Diseases: Shaping Future Trends

08:30  Session Chair
Prof. Kelly CHIBALE  
(UNIVERSITY OF CAPE TOWN, Cape Town, South Africa)

08:35  Update on Chemotherapy of Tropical Diseases Caused by Protozoan Parasites
Prof. Reto BRUN  
(SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE, Basel, Switzerland)

09:15  Antimalarial Trioxolanes - Exploiting Peroxide Reduction For Parasite-Selective Drug Delivery
Dr Adam RENSLO  
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

09:35  Antimalarial Lead Discovery from phenotypic screening: Unraveling the Black Box
Dr Francisco-Javier GAMO  
(GLAXOSMITHKLINE, Madrid, Spain)

09:55  Improving Physiochemical Properties of a Lapatinib-Based Lead Compound that Targets Trypanosoma Brucei
Prof. Jennifer WOODRING  
(NORTHEASTERN UNIVERSITY, Boston, United States)

Session 8.22 New Therapies for Metabolic Disorders

08:30  Session Chair
Dr Jürgen MACK  
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)

08:35  Pharmaceutical Protein & Peptide Engineering: From Once Daily To Once Weekly GLP-1 Dosing
Dr Jesper LAU  
(NOVO NORDISK, Maaaloev, Denmark)

09:15  1,1’-Spiro-Substituted Hexahydrofuroquinoline Derivatives As Potent And Polar Cholesteryl Ester Transfer Protein (CETP) Inhibitors
Dr Thomas TRIESELMANN  
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany)

09:35  Omargliptin: A Once-weekly Oral Antidiabetic Agent
Dr Tesfaye BIFTU  
(MERCK, Rahway, United States)

09:55  Discovery of GPR103 Ligands Demonstrating the Anorexigenic Effect in vivo of GPR103 Antagonism
Dr Anneli NORDQVIST  
(ASTRAZENECA, BIOPHARMACEUTICALS R&D, Gothenburg, Sweden)
10:15 Exhibition & Coffee & Snacks

Session 9.23 Late Breaking News

10:45 Session Chair
Dr Laurence LAFANECHERE
(CNRS, Grenoble, France)

10:50 CHF-6001, an Inhaled PDE4 Inhibitor for Asthma and COPD: Synthesis, In Vitro and In Vivo Characterization
Dr Maurizio DELCANALE
(CHIESI, Parma, Italy)

11:10 The Discovery of AZD5069; a CXCR2 Antagonist In Phase II Clinical Trials for the Treatment of Asthma
Dr Rhona COX
(ASTRAZENECA, Mölndal, Sweden)

11:30 Discovery of BAY 85-8501, a Novel and Highly Potent Induced-Fit Binder of Human Neutrophil Elastase for Pulmonary Diseases
Dr Franz VON NUSSBAUM
(BAYER PHARMA, Berlin, Germany)

11:50 Discovery of TD-5959 (Batefenterol/GSK-961081): A First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and Beta-2 Agonist (MABA) for the Treatment of COPD
Dr Adam HUGHES
(THERAVANCE INC., South San Francisco, United States)

12:10 Identifying Selective Inhibitors of FGFR4 Kinase
Dr Kurt PIKE
(ASTRAZENECA, Cambridge, United Kingdom)

Session 9.24 Neurodegeneration: Deeper Understanding of Disease Biology and Emerging Therapeutic Options

10:45 Session Chair
Dr Andrew THOMAS
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

10:50 CaV1.3-Selective L-Type Calcium Channel Negative Allosteric Modulators. Novel Therapeutics to Slow the Progression of Parkinson’s Disease
Prof. Rick SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, United States)

11:30 Restoration of Muscle Mass and Lifespan in a Mouse Model of Spinal Muscular Atrophy by Molecular Correction of SMN2 Splicing Defect
Dr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

11:50 Fragment-Based Discovery of BACE Inhibitors for Alzheimer’s Disease
Dr Andrew STAMFORD
(MERCK RESEARCH LABORATORIES, Rahway, United States)

12:10 The Evolution of an in vivo Efficacious Bace1 Inhibitor
Dr Daniel OEHLRICH
(JANSSEN RESEARCH AND DEVELOPMENT, Beerse, Belgium)

Session 9.25 Translational Medicine: Case Studies with Biomarkers and PKPD Modeling

10:45 Session Chair
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

10:50 Translational Modeling in Support to Discovery and Early Development
Dr Thierry LAVE
(F.HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

11:30 Non-Clinical Characterization And Clinical Translation Of LY2811376 And LY2886721
Dr Dustin James MERGOTT
(ELI LILLY, Indianapolis, United States)

11:50 A HTS Assay Predicting Both Passive Intestinal Absorption and Affinity Constant Towards Human Serum Albumin in a Two End-Point Measurement
Mr Alban BUJARD  
(UNIVERSITY OF GENEVA, Geneva, Switzerland)

12:10 Biomarkers after Bacteriochlorin Based Photodynamic Therapy against Cancer  
Dr Martyna KRZYKAWSKA-SERDA  
(FACULTY OF BIOCHEMISTRY, BIOPHYSICS AND BIOTECHNOLOGY, JAGIELLONIAN UNIVERSITY, Krakow, Poland)

12:30 Closing Lecture  
Personalised Medicinal Systems Chemistry  
Prof. Hans WESTERHOFF  
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

13:15 Closing Remarks, Poster Prizes and Welcome to EFMC-ISMC 2016